



The  
University  
Of  
Sheffield.

# Case Studies and Exemplars of Efficient Study Designs in Clinical Trials

Professor Steven A. Julious

Medical Statistics Group,  
School of Health and Related Research,  
University of Sheffield

© Steven A. Julious



The  
University  
Of  
Sheffield.

## With thanks to

- Munya Dimairo, Laura Flight, Annabel Allison, Feng Liu, Ben Sully, Abigail Stevely, Isabella Hatfield and Amy Whitehead

© Steven A. Julious



# Introduction

- Definition of an Efficient Design
- Case studies
  - Replication
  - PLEASANT
  - Using early data
  - RATPAC (Re-analysis)
  - Adaptive Designs
  - Futility
- Discussion and Conclusions

© Steven A. Julious



## What is an Efficient Design?

- An umbrella term for smarter ways of doing trials
- Using routine data
- Early data
- Being adaptive
- Simple design enhancements

© Steven A. Julious

# Replication in Cross-over trials


© Steven A. Julious

# Replication in Cross-over studies



- A two treatment cross-over study may be done in a two period study of two sequences AB BA
- Is the AB BA design out of tune with what is required?
  - A three period replicate design would require 25% less patients
  - A four period replicated design 50% less

© Steven A. Julious

## Comparison of two formulations of Ropinerole



## Using Routine Data



# Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term

© Steven A. Julious



PLEASANT

© Steven A. Julious

## The PLEASANT Trial

- It is a National Health Service (NHS) delivered public health intervention in a primary care setting in 142 GP practices
- Used routine data and the Clinical Practice Research Datalink (CPRD) to collect the data
- More efficient than need to contact individual practices to collect data


© Steven A. Julious

## Adaptive Design Case Study

© Steven A. Julious



## Group Sequential Design - Concept



© Steven A. Julious



## What was Good About this Study?

© Steven A. Julious

## **Recruitment was Controlled by the Sponsor**

- Subjects were recruited and enrolled into a single centre and a rate fixed by sponsor
  - Planning for the analysis was straightforward
  - Time lines preset
- How much more time consuming if this is not the case?
- What if recruitment continued whilst interim taking place?

© Steven A. Julious

## **Endpoint in the Interim Analysis was the Same as in the Final Analysis**

- Could be using a surrogate
  - For example an imaging endpoint for interim analysis
  - Or the main outcome measured at an earlier time point...
- Could analyse a primary endpoint but assessed at an earlier time point
  - How predictive is this of response?

© Steven A. Julious



The  
University  
Of  
Sheffield.

# A Cohort Randomised Trial

© Steven A. Julious



The  
University  
Of  
Sheffield.

## Example Dosing Cohorts

### Cohort 1

D1	D1	D1	D1	D1	D1	D1	D1	D1	D1	D1	D1	D1	P	P	P	P	P	P
----	----	----	----	----	----	----	----	----	----	----	----	----	---	---	---	---	---	---

### Cohort 2

D2	D2	D2	D2	D2	D2	D2	D2	D2	D2	D2	D2	D2	P	P	P	P	P	P
----	----	----	----	----	----	----	----	----	----	----	----	----	---	---	---	---	---	---


### Cohort 3

D3	D3	D3	D3	D3	D3	D3	D3	D3	D3	D3	D3	D3	P	P	P	P	P	P
----	----	----	----	----	----	----	----	----	----	----	----	----	---	---	---	---	---	---


etc

© Steven A. Julious

## Schematic of Dose Response



## Dose Response by Day




© Steven A. Julious




The  
University  
Of  
Sheffield.

## Individual Data Analysis



The  
University  
Of  
Sheffield.

## Meta Analysis of 20 Studies





# The RATPAC Trial

© Steven A. Julious




# The RATPAC Trial

- Randomised Assessment of Treatment Using Panel Assay of Cardiac Markers (RATPAC) trial was in an Emergency Care setting
- Primary endpoint was successful discharge within 4 hours with no re-admission within 3 months

© Steven A. Julious

## Re-analysis or RATPAC



© Steven A. Julious

## RATPAC Results

	Original RATPAC	Group Sequential RATPAC*
Estimated POC success, %	32	32
Estimated SC success, %	13	16
Pearson $\chi^2$ statistic	112.25, $P < .001$	29.69, $P < .001$
Odds ratio (95% CI)	3.11 (2.59–3.72)	2.48 (1.80–3.42)
Sample size at termination	2,243	772
Duration, mo	18	6

POC, Point-of-care; SC, standard care.

\*Group sequential results shown for the final (updated) endpoint.

© Steven A. Julious

# The ESETT Trial

© Steven A. Julious

# The ESETT Trial

Established status epilepticus treatment trial (ESETT): A pragmatic randomised controlled comparison of phenytoin, valproate or levetiracetam in established status epilepticus where initial benzodiazepine treatment has failed

© Steven A. Julious

## Comparisons of Interest

- Comparison 1: Valproate vs. Phenytonin
- Comparison 2: Levetircetam vs. Phenytonin
- Comparison 3: Levetircetam vs. Valproate

© Steven A. Julious


## Testing Procedure

- Statistical significance to be declared if both comparisons 1 and 2 are significant at the 5% level or if either comparison is significant at the 2.618% level.
- Comparison 3 will be tested at a 5% level of significance if both Comparison 1 and Comparison 2 are statistically significant at 5%


© Steven A. Julious

# Trial Simulations


a. Comparisons 1 and 2




b. Comparison 3



c. Comparisons 2



d. Comparison 1



## (SARA: Steroids for Allergic Reaction and Anaphylaxis)

Double blind randomised controlled trial of systemic corticosteroids for systemic allergic reaction or anaphylaxis

## SARA Sample Size

The trial will actually be analysed as a group sequential trial with 5 scheduled analyses at N=360, 720, 1080, 1440 and 1800. The maximum sample size to provide 90% power using this approach is 1800 in total, but the expected sample size will be 1024 if the assumed difference of 92% versus 96% is true or 800 if both arms have a 92% success rate.

© Steven A. Julious

## SARA Simulations

To investigate the properties of the design simulations were undertaken Assuming the effect on placebo is 92% simulations were used investigate at which analysis (1st, 2nd, 3rd, 4th or 5th) 50% of trials would be anticipated to stop

It is anticipated that trials would stop 50% or more of the time after the 2nd, 2nd, 2nd, 3rd, 3rd and 3rd interim analysis for effects of 99%, 98%, 97%, 96%, 95% and 94% respectively.

© Steven A. Julious

## SARA Costings

- The total research costs will be £838,714 if the trial is terminated at 27 months (N=360), £1,136,893 for 32 months (N=720) £1,340,174 for 37 months (N=1080), £1,556,588 for 42 months (N=1440) and £1,685,663 for the maximum 46 months (N=1800)

© Steven A. Julious

## Nerve Block Trial

- An adaptive, factorial, double blind randomised placebo controlled trial of bilateral superficial plexus nerve block (BSCPb) and local wound infiltration (LWI) for pain relief following thyroid and parathyroid surgery.
- Adaptive component allowed for a pre-planned change in strategy dependent on results of interim analyses, enabling a flexible and efficient trial design that addresses important clinical questions.

## The PENNYWISE Trial


- Prolonged Enoxaparin in primary percutaneous coronary intervention compared With Standard-of-care Bivalirudin therapy - the PENNYWISE study
- An adaptive non-inferiority trial with interim analyses after 50 and 75% of patients recruited

© Steven A. Julious

## Obstacles to Adaptive Designs

© Steven A. Julious

## CTRU Obstacles to Adaptive Designs



© Steven A. Julious

## What are the low hanging fruit?



- Group Sequential trials to assess efficacy and futility
- Sample Size re-estimation

© Steven A. Julious

## The Utility of Futility

- In the UK 55% of all publicly funded trials do not reach their target sample size
  - Studies with 80% power are less likely to recruit to target
- For publicly funded superiority trials a futility assessment would increase successful recruitment from 45% to 64%

© Steven A. Julious

## Summary

- Proficient
- Efficient
- Sufficient
- Deficient

© Steven A. Julious

